NCT06638931 2026-04-15ANTARESInstituto do Cancer do Estado de São PauloPhase 2 Recruiting28 enrolled
NCT00947167 2017-03-03A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine TumorsStanford UniversityPhase 2 Terminated4 enrolled 5 charts